Thrombotic risk assessment in antiphospholipid syndrome: the role of new antibody specificities and thrombin generation assay
Savino Sciascia(Ospedale San Giovanni Bosco), Dario Roccatello(5T Torino (Italy)), Elisa Menegatti(Azienda Ospedaliero Universitaria San Giovanni Battista), Laura Solfietti(Azienda Ospedaliero Universitaria San Giovanni Battista), Massimo Radin(Ospedale San Giovanni Bosco), Karen Schreiber(Guy's and St Thomas' NHS Foundation Trust), Doruk Erkan(Hospital for Special Surgery), María José Cuadrado(Guy's and St Thomas' NHS Foundation Trust), Simone Baldovino(Azienda Ospedaliero Universitaria San Giovanni Battista)
Cited by 48
Related Papers
GAPSS: the Global Anti-Phospholipid Syndrome Score
|Lara D. Veeken|2013|310
Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study
|Arthritis & Rheumatology|2021|165
HYdroxychloroquine to Improve Pregnancy Outcome in Women with AnTIphospholipid Antibodies (HYPATIA) Protocol: A Multinational Randomized Controlled Trial of Hydroxychloroquine versus Placebo in Addition to Standard Treatment in Pregnant Women with Antiphospholipid Syndrome or Antibodies
|Seminars in Thrombosis and Hemostasis|2017|125
Assessment of the 2006 revised antiphospholipid syndrome classification criteria
|Annals of the Rheumatic Diseases|2007|95
Progressive multiple sclerosis, cognitive function, and quality of life
|Brain and Behavior|2018|94